Oscillo Biosciences
Farmington
About Oscillo Biosciences
Oscillo Biosciences develop pharmacological treatments for Alzheimer's disease and related disorders. Oscillo Biosciences conducted a phase 1 study to evaluate the effectiveness of music and multisensory stimulation on brain activity in adults. Oscillo Biosciences creates a prescription medical device and a digital therapeutic that work together to restore healthy brain function in patients suffering from mild cognitive impairment and Alzheimer's disease. The approach of Oscillo Biosciences is based on the understanding that brain rhythms supporting memory and cognition are disrupted in people with Alzheimer's disease.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $389.8K
- Funding stage: Seed
- Last round: Grant (May 2020)
- Website: oscillobiosciences.com
- Phone: 1 860-282-4215
Industries & Categories
Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/oscillo-biosciences-152559 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.